Silodosin filed for Chinese approval
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas submitted an approval application to China's State FDA for the alpha 1a-adrenoceptor antagonist silodosin, for the treatment of dysuria associated with benign prostatic hyperplasia. The oral product is licensed from originatorKissei, with which Daiichi Sankyo co-markets it in Japan as Urief. Licensee Recordati filed for EU approval in November and Watson Pharmaceuticals received marketing clearance (as Rapaflo) in the US, Canada and Mexico in the previous month.